IMMUNITYBIO, INC. Interest Expense, Other
IMMUNITYBIO, INC. (IBRX) reported Interest Expense, Other of $17.19 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseOther · last filed 2026-08-04
- IMMUNITYBIO, INC. interest expense, other for the quarter ending 2026-06-30 was $17.19M, a 28.25% increase year-over-year.
- IMMUNITYBIO, INC. interest expense, other for the quarter ending 2026-03-31 was $13.87M, a 2.49% increase year-over-year.
- IMMUNITYBIO, INC. interest expense, other for the quarter ending 2025-12-31 was $12.30M, a 6.92% increase year-over-year.
- IMMUNITYBIO, INC. interest expense, other for the quarter ending 2025-09-30 was $12.30M, a 12.60% increase year-over-year.
- IMMUNITYBIO, INC. interest expense, other for fiscal 2025 was $51.54M, a 29.96% increase from fiscal 2024.
- IMMUNITYBIO, INC. interest expense, other for fiscal 2024 was $39.66M, a 14921.59% increase from fiscal 2023.
- IMMUNITYBIO, INC. interest expense, other for fiscal 2023 was $264.00K, a 200.00% increase from fiscal 2022.
- IMMUNITYBIO, INC. interest expense, other for fiscal 2022 was $88.00K, a 4.35% decline from fiscal 2021.
| Period end | Interest Expense, Other 3 month | Interest Expense, Other 3 month as first filed | Interest Expense, Other 6 month | Interest Expense, Other 6 month as first filed | Interest Expense, Other 9 month | Interest Expense, Other 9 month as first filed | Interest Expense, Other 12 month | Interest Expense, Other 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $17.19M 10-Q · filed 2026-08-04 | $31.06M 10-Q · filed 2026-08-04 | $43.36M derived: sum of 3 quarters · filed 2026-08-04 | $55.66M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2026-03-31 | $13.87M 10-Q · filed 2026-05-07 | $26.17M derived: sum of 2 quarters · filed 2026-05-07 | $38.47M derived: sum of 3 quarters · filed 2026-05-07 | $51.88M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-12-31 | $12.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $24.60M derived: sum of 2 quarters · filed 2026-02-23 | $38.01M derived: sum of 3 quarters · filed 2026-08-04 | $51.54M 10-K · filed 2026-02-23 | ||||
| 2025-09-30 | $12.30M 10-Q · filed 2025-11-05 | $25.71M derived: sum of 2 quarters · filed 2026-08-04 | $39.24M 10-Q · filed 2025-11-05 | $50.74M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-06-30 | $13.40M 10-Q · filed 2026-08-04 | $26.94M 10-Q · filed 2026-08-04 | $38.44M derived: sum of 3 quarters · filed 2026-08-04 | $49.37M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | $13.53M 10-Q · filed 2026-05-07 | $25.04M derived: sum of 2 quarters · filed 2026-05-07 | $35.96M derived: sum of 3 quarters · filed 2026-05-07 | $45.19M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $11.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $22.43M derived: sum of 2 quarters · filed 2026-02-23 | $31.65M derived: sum of 3 quarters · filed 2026-02-23 | $39.66M 10-K · filed 2026-02-23 | $82.00K 10-K · filed 2025-03-03 | |||
| 2024-09-30 | $10.93M 10-Q · filed 2025-11-05 | $0.00 10-Q · filed 2024-11-12 | $20.15M derived: sum of 2 quarters · filed 2025-11-05 | $28.15M 10-Q · filed 2025-11-05 | $32.00K 10-Q · filed 2024-11-12 | $28.37M derived: sum of 4 quarters · filed 2026-02-23 | ||
| 2024-06-30 | $9.22M 10-Q · filed 2025-08-05 | $7.00K 10-Q · filed 2024-08-12 | $17.23M 10-Q · filed 2025-08-05 | $32.00K 10-Q · filed 2024-08-12 | $17.45M derived: sum of 3 quarters · filed 2026-02-23 | $17.47M derived: sum of 4 quarters · filed 2026-02-23 | ||
| 2024-03-31 | $8.00M 10-Q · filed 2025-05-12 | $25.00K 10-Q · filed 2024-05-09 | $8.22M derived: sum of 2 quarters · filed 2026-02-23 | $8.24M derived: sum of 3 quarters · filed 2026-02-23 | $8.25M derived: sum of 4 quarters · filed 2026-02-23 | |||
| 2023-12-31 | $220.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $239.00K derived: sum of 2 quarters · filed 2026-02-23 | $244.00K derived: sum of 3 quarters · filed 2026-02-23 | $264.00K 10-K · filed 2026-02-23 | $349.00K 10-K · filed 2024-03-19 | |||
| 2023-09-30 | $19.00K 10-Q · filed 2024-11-12 | $24.00K derived: sum of 2 quarters · filed 2024-11-12 | $44.00K 10-Q · filed 2024-11-12 | $81.00K derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-06-30 | $5.00K 10-Q · filed 2024-08-12 | $25.00K 10-Q · filed 2024-08-12 | $62.00K derived: sum of 3 quarters · filed 2025-03-03 | $88.00K derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-03-31 | $20.00K 10-Q · filed 2024-05-09 | $57.00K derived: sum of 2 quarters · filed 2025-03-03 | $83.00K derived: sum of 3 quarters · filed 2025-03-03 | $88.00K derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | $37.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $63.00K derived: sum of 2 quarters · filed 2025-03-03 | $68.00K derived: sum of 3 quarters · filed 2025-03-03 | $88.00K 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | $26.00K 10-Q · filed 2023-11-09 | $31.00K derived: sum of 2 quarters · filed 2023-11-09 | $51.00K 10-Q · filed 2023-11-09 | $91.00K derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-06-30 | $5.00K 10-Q · filed 2023-08-08 | $25.00K 10-Q · filed 2023-08-08 | $65.00K derived: sum of 3 quarters · filed 2024-03-19 | $86.00K derived: sum of 4 quarters · filed 2024-03-19 | ||||
| 2022-03-31 | $20.00K 10-Q · filed 2023-05-11 | $60.00K derived: sum of 2 quarters · filed 2024-03-19 | $81.00K derived: sum of 3 quarters · filed 2024-03-19 | |||||
| 2021-12-31 | $40.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $61.00K derived: sum of 2 quarters · filed 2024-03-19 | $92.00K 10-K · filed 2024-03-19 | |||||
| 2021-09-30 | $21.00K 10-Q · filed 2022-11-09 | $52.00K 10-Q · filed 2022-11-09 | ||||||
| 2020-12-31 | $41.00K 10-K · filed 2023-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |